Novo Nordisk

• Novo Nordisk’s CagriSema outperforms Ozempic in Phase III trial - While the drug also previously succeeded in two obesity studies, it fell short of expectations at the time.
• The disruptive force of weight loss drugs: How GLP-1s do more than shed pounds - The impacts of weight-loss medications reach far beyond the realm of health and wellness
• EU must push for 'Made in Europe' strategy, EU industry chief says - Feb 2 (Reuters) - Europe needs to protect its own industries with a "Made in Europe" strategy, EU industry chief Stephane Sejourne said in a newspaper article published late on Sunday, co-signed by
• Pfizer CEO plans for soaring consumer market for obesity drugs akin to Viagra - SAN FRANCISCO, Jan 12 (Reuters) - Pfizer is preparing for a consumer market for obesity drugs on par with the booming business it saw after it launched erectile dysfunction drug ​Viagra in 1998, CEO Albert Bourla said on Monday. Bourla said
• Canadian pharmacy platform to offer India-sourced Ozempic to US patients - By Siddhi Mahatole Jan 7 (Reuters) - Online pharmacy platform SaveRxCanada.to said on Wednesday it has begun offering Novo Nordisk's blockbuster diabetes drug, Ozempic, sourced from India to U.S.
• Wegovy weight loss pill now available: How to get it and the cost - The oral medication serves as an alternative to the injectable version.
• Exclusive-Novo Nordisk's US public affairs head leaves company, memo shows - LONDON/SAN FRANCISCO, Jan 5 (Reuters) - Danish obesity drugmaker Novo Nordisk's head of public affairs in the U. has left the company, ​according to an internal memo seen by Reuters, at a time when the firm ‌is battling to revive its fortun
• Novo Nordisk to sell Wegovy pill to US self-pay patients starting at $149 per month - COPENHAGEN, Jan 5 () - Denmark's Novo Nordisk will offer its 1.5 ​and 4 milligram Wegovy weightloss pills ‌at $149 per month to self-paying patients in ‌the United States from January 5, it said on Monday.
• FDA Approves Oral Version of Wegovy, First GLP-1 Pill Approved Specifically for Weight Management - The pill is expected to be available starting in January 2026.
• Should You Invest in Ozempic Maker Novo Nordisk in 2026? - The pharmaceutical giant's stock has tumbled over the past year and a half, but it could be poised to storm back.